Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011.

Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, Dobre D, Denig P.

Drug Saf. 2011 Dec 1;34(12):1191-202. doi: 10.2165/11593810-000000000-00000.

PMID:
22077507
2.

A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients.

Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, Dobre D, Denig P.

Health Qual Life Outcomes. 2011 Sep 29;9:83. doi: 10.1186/1477-7525-9-83. Review.

3.

Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study.

de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P.

Health Qual Life Outcomes. 2014 Aug 13;12:103. doi: 10.1186/s12955-014-0103-6.

4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter S, Greyber E, Pasternak G, Salpeter E.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002967. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD002967.

PMID:
16437448
6.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter S, Greyber E, Pasternak G, Salpeter E.

Cochrane Database Syst Rev. 2003;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD002967.

PMID:
12804446
7.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter S, Greyber E, Pasternak G, Salpeter E.

Cochrane Database Syst Rev. 2002;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2003;(2):CD002967.

PMID:
12076461
8.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

PMID:
22411919
9.

Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.

Sobieraj DM, Freyer CW.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1334-7. doi: 10.1345/aph.1P148. Epub 2010 Jun 1.

PMID:
20516361
10.
11.
12.
13.

Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP.

Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Review.

PMID:
24338344
14.

Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.

Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N.

PLoS One. 2014 Feb 12;9(2):e82880. doi: 10.1371/journal.pone.0082880. eCollection 2014. Review.

15.

The validity of a patient-reported adverse drug event questionnaire using different recall periods.

de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P.

Qual Life Res. 2014 Nov;23(9):2439-45. doi: 10.1007/s11136-014-0715-7. Epub 2014 May 22.

PMID:
24848596
16.

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA.

Drug Saf. 2009;32(5):409-18. doi: 10.2165/00002018-200932050-00004.

PMID:
19419235
17.

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL.

Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.

PMID:
17638715
18.

Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus.

Kovatchev B, Umpierrez G, DiGenio A, Zhou R, Inzucchi SE.

J Diabetes Sci Technol. 2015 Jun 15;9(6):1227-35. doi: 10.1177/1932296815587014.

19.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter SR, Greyber E, Pasternak GA, Salpeter EE.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Review.

PMID:
20393934
20.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967. doi: 10.1002/14651858.CD002967.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(4):CD002967.

PMID:
20091535

Supplemental Content

Support Center